Schedule 13D ownership disclosure

Monte Rosa Therapeutics Inc

Common Stock, par value $0.0001 per share · CUSIP: 61225M102

Event date: 2025-11-10

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Versant Venture Capital VI, L.P.Reported CIK 0001687880

    Shares: 3,334,669 · Class: 5.1%

  • Versant Ventures VI GP, L.P.Reported CIK 0001777654

    Shares: 3,334,669 · Class: 5.1%

  • Versant Ventures VI GP-GP, LLCReported CIK 0001777652

    Shares: 3,334,669 · Class: 5.1%

  • Versant Vantage I, L.P.

    Shares: 1,573,453 · Class: 2.4%

  • Versant Vantage I GP, L.P.

    Shares: 1,573,453 · Class: 2.4%

  • Versant Vantage I GP-GP, LLC

    Shares: 1,573,453 · Class: 2.4%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193125-25-277603
Form type
SCHEDULE 13D/A
Filer
Monte Rosa Therapeutics, Inc.
CIK
CIK 1826457
Filed
Nov 12, 2025
Reporting period
Nov 10, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub